loader image
Monday, October 6, 2025
76.5 F
McAllen
- Advertisement -

Long-acting Antibody Treatment vs. Omicron Variant in Patients with Compromised Immune System

Translate to Spanish or other 102 languages!

DHR Health Institute for Research and Development is currently offering long-acting monoclonal antibody treatment to PREVENT COVID-19 in high-risk patients. Image for illustration purposes.
DHR Health Institute for Research and Development is currently offering long-acting monoclonal antibody treatment to PREVENT COVID-19 in high-risk patients. Image for illustration purposes.

Mega Doctor News

- Advertisement -

EDINBURG, TX – DHR Health Institute for Research and Development is currently offering long-acting monoclonal antibody treatment to PREVENT COVID-19 in high-risk patients. This is the only treatment currently available to prevent infection by the Omicron variant of SARS-CoV-2…the virus that causes COVID-19.

On December 8, 2021, the U.S. Food and Drug Administration issued an Emergency Use Authorization allowing the use of AstraZeneca’s long-acting antibody EVUSHELDTM to be used for prevention of COVID-19 in subjects 12 years and older with moderate to severe immunocompromised status before exposure to the virus.

“The majority of the patients who are currently hospitalized with severe COVID-19 are those who are unvaccinated, and those who are vaccinated, but have a compromised immune system” said Sohail Rao, MD, MA, DPhil, President and CEO, DHR Health Institute for Research & Development. “Given that Omicron is the dominant variant which is responsible for the current spike in COVID-19 cases in the US and globally, EVUSHELDTM is the only antibody that can offer long-term protection against this variant in patients with weakened immune system”

- Advertisement -

I

Long-acting Antibody Treatment vs. Omicron Variant in Patients with Compromised Immune SystemTreatment with this long-acting antibody will provide patients with protection against SARS-CoV-2 (including its Omicron variant) for up to 6-9 months. In the last few weeks, we have treated over 50 patients at DHR Health with this monoclonal antibody with a very satisfactory outcome.

If you or your patient is interested to receive this treatment or need to discuss their condition further, please call 956-342-4896 or download the contact information by using this QR Code: 

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Ignoring cholesterol until middle age is a bad idea

Unhealthy cholesterol levels are a major risk factor for heart disease and stroke. Bowers, now a nursing professor at Purdue University Northwest in Hammond, Indiana, has attempted to address the issue. But she agreed cholesterol management is not something young adults usually worry about.

DHR Health Breast Cancer Symposium, Oct. 11th 

To support providers in the community, the DHR Health Continuing Medical Education Department will host the Breast Cancer Symposium on Saturday, October 11, at the Edinburg Conference Center at Renaissance, located at 118 Paseo del Prado.

STHS Children’s to Host Monster Jam Patient Meet & Greet, Oct. 9th

On Thursday, October 9, 2025, from 2:00 – 4:00 p.m., the pediatric patients at South Texas Health System Children’s will have the opportunity to experience monster truck magic without leaving the hospital grounds.

Daily combo of water, coffee, and tea linked to longevity

water does not only have to come from the ubiquitous water bottle — other drinks and food can provide a good proportion of your daily needs.
- Advertisement -
×